Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jade Biosciences, Inc. (JBIO : NSDQ)

• Company Description    Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $9.19 Daily Weekly Monthly 20 Day Moving Average: 198,535 shares Shares Outstanding: 32.63 (millions) Market Capitalization: $299.84 (millions) Beta: 1.07 52 Week High: $13.50 52 Week Low: $2.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.21% -1.44% 12 Week 24.86% 19.69% Year To Date -90.12% -91.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - Waltham,MA 02453 USA ph: 781-312-3013 fax: - info@jadebiosciences.com https://jadebiosciences.com

• General Corporate Information    Officers Timothy P. Noyes - Chief Executive Officer and Director George A. Eldridge - Chief Financial Officer Habib Dable - Director Allison Dorval - Director David Grayzel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 008064206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 32.63 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.07 Market Capitalization: $299.84 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 97.15% vs. Previous Quarter: 72.77% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -51.96 03/31/25 - -60.01 ROA 09/30/25 - - 06/30/25 - -47.65 03/31/25 - -54.32 Current Ratio 09/30/25 - - 06/30/25 - 10.31 03/31/25 - 32.01 Quick Ratio 09/30/25 - - 06/30/25 - 10.31 03/31/25 - 32.01 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 6.18 03/31/25 - 89.28 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©